A new FAERS analysis reports disproportionate gastrointestinal hypomotility reporting for GLP-1 receptor agonists and tirzepatide, including reports of ileus and obstruction. The database review notes distinct onset timelines between agent classes, highlighting how routine postmarketing surveillance can surface safety questions beyond trial populations. The findings focus on a symptom cluster consistent with impaired gastrointestinal motility, which has been a recurring concern for metabolic drugs that act on gut-brain pathways. The FAERS signal does not establish incidence rates or causality, but it strengthens the case for targeted clinician awareness and risk-management strategies. For biotech and pharma leaders, the work underscores the importance of monitoring real-world adverse event patterns as these drug classes expand across indications.
Get the Daily Brief